Our data show that selected 3-bromo-isoxazoline derivatives are able to penetrate cancer cells and to bind and inhibit the GAPDH enzyme altering the cancer metabolic profile and decreasing cancer-cell growth, without affecting normal cells. This evidence concerns the gene GAPDH and cancer.